Latest Breaking News On - Anheart therapeutics inc - Page 1 : comparemela.com

Form 10-K Nuvalent, Inc. For: Dec 31

Form 10-K Nuvalent, Inc. For: Dec 31

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

/PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting

Share: HANGZHOU, China and NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) AnHeart Therapeutics Co., Ltd. ( AnHeart ), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually on June 4-8, 2021. Details on the abstract and a corresponding poster presentation are shown below. Abstract Number: 9066 Abstract Title: Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting